The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

October 21, 2015 • By Lorraine L. Janeczko

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to other biologic treatments, a study from Italy suggests.

You Might Also Like
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

With its convenient dosing schedule, rituximab may be a new treatment option for patients with autoimmune diseases, especially for those who have not responded to tumor necrosis factor alpha (TNF-alpha) blockers, the authors, led by Dr. Elisabetta Miserocchi of the department of ophthalmology at the University Vita-Salute in Milan wrote in an article online Sept. 22 in the British Journal of Ophthalmology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This is an interesting study describing the long-term experience of this group of researchers in the management of sight-threatening uveitis associated with JIA. JIA-uveitis can be a serious disease and if untreated may lead to blindness,” Dr. John V. Forrester, ophthalmologist and emeritus professor at the University of Aberdeen, Scotland, told Reuters Health by email.

“A small subset of these patients fails to respond to anti-TNFs, which is why this paper is encouraging, particularly since it has been shown that the eye inflammation can be controlled long term by repeated infusions of the alternative biologic, rituximab, at regular intervals. This new treatment seems to be quite well tolerated and has been used in other conditions relatively safely,” said Dr. Forrester, who was not involved in the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Miserocchi and colleagues conducted a retrospective study of the case records of 15 eyes in eight patients who had severe, long-standing JIA-associated uveitis and inadequate uveitis control by one or more biologic agents, including at least one TNF blocker and/or abatacept. The patients ranged in age from 16 to 34 years, with a mean of 22.8. Six were female, and all were Caucasian.

The mean ocular disease duration was 17.7 years; the mean follow-up time on rituximab was 44.75 months; and the mean number of rituximab infusions received was 8.75 (range 6 to 12). All patients achieved complete uveitis control, but two patients discontinued rituximab due to its inefficacy in treating arthritis.

All patients received 1,000 mg infusions of rituximab on days one and 15 and every six months thereafter to maintain long-term quiescence and avoid uveitis recurrence. To reduce the risk of infusion reactions, they also received 100 mg of intravenous methylprednisolone, oral paracetamol and antihistamines before their infusions.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers assessed the patients’ clinical responses to treatment, including uveitis activity decrease, visual acuity changes, related local and systemic corticosteroid and/or immunosuppressant reduction, and adverse events.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Anti-TNF, Juvenile Arthritis (JIA), rituximab, TNF, Uveitis

You Might Also Like:
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
  • Health Canada Approves Adalimumab for Chronic Non-Infectious Anterior Uveitis in Pediatric Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)